Metal-organic frameworks with exceptionally large pore aperatures
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/00
A61K-047/24
C07F-003/02
C07F-003/06
B01J-020/22
B01D-053/02
C02F-001/28
C07F-005/02
C07K-014/435
C07F-007/22
B01J-020/28
B01J-020/02
출원번호
US-0797312
(2015-07-13)
등록번호
US-9669098
(2017-06-06)
발명자
/ 주소
Yaghi, Omar M.
Furukawa, Hiroyasu
Deng, Hexiang
출원인 / 주소
The Regents of the University of California
대리인 / 주소
Gavrilovich, Dodd & Lindsey LLP
인용정보
피인용 횟수 :
0인용 특허 :
27
초록
The disclosure relates to metal organic frameworks or isoreticular metal organic frameworks, methods of production thereof, and methods of use thereof.
대표청구항▼
1. A composition comprising a pharmaceutically active agent and a MOF or IRMOF comprising the general structure M-L-M, wherein M comprises a metal and L is a linking moiety of Formula I: wherein, A1-A8 are independently either N or C;X1 and X2 are functional groups (FG);R1-R12 are independently sel
1. A composition comprising a pharmaceutically active agent and a MOF or IRMOF comprising the general structure M-L-M, wherein M comprises a metal and L is a linking moiety of Formula I: wherein, A1-A8 are independently either N or C;X1 and X2 are functional groups (FG);R1-R12 are independently selected from the group comprising H, FG, (C1-C12)alkyl, substituted (C1-C12)alkyl, (C1-C12)alkenyl, substituted (C1-C12)alkenyl, (C1-C12)alkynyl, substituted (C1-C12)alkynyl, hetero-(C1-C12)alkyl, substituted hetero-(C1-C12)alkyl, hetero-(C1-C12)alkenyl, substituted hetero-(C1-C12)alkenyl, hetero-(C1-C12)alkynyl, substituted hetero-(C1-C12)alkynyl, (C1-C12)cycloalkyl, substituted (C1-C12)cycloalkyl, aryl, substituted aryl, heterocycle, substituted heterocycle, —C(R13)3, —CH(R13)2, —CH2R13, —C(R13)3, —CH(R14)2, —CH2R14, —OC(R13)3, —OCH(R13)2, —OCH2R14, —OC(R14)3, —OCH(R14)2, —OCH2(R14), wherein R1 and R2 are linked together to form a substituted or unsubstituted ring selected from the group comprising cycloalkyl, aryl and heterocycle, and wherein R3 and R4 are linked together to form a substituted or unsubstituted ring selected from the group comprising cycloalkyl, aryl and heterocycle; R13 is selected from the group comprising FG, (C1-C12)alkyl, (C1-C12)substituted alkyl, (C1-C12)alkenyl, substituted (C1-C12)alkenyl, (C1-C12)alkynyl, substituted (C1-C12)alkynyl, hetero-(C1-C12)alkyl, substituted hetero-(C1-C12)alkyl, hetero-(C1-C12)alkenyl, substituted hetero-(C1-C12)alkenyl, hetero-(C1-C12)alkynyl, substituted hetero-(C1-C12)alkynyl, hemiacetal, hemiketal, acetal, ketal, and orthoester;R14 is one or more substituted or unsubstituted rings selected from the group comprising cycloalkyl, aryl, and heterocycle;y is a number from 0 to 3;z is a number from 0 to 20; andwith the proviso that R is absent when bound to an A that is N; andwherein the pharmaceutically active agent is located with pores of the MOF or IRMOF. 2. The composition of claim 1, wherein M is either a transition metal or an alkaline earth metal. 3. The composition of claim 1, wherein M is either Mg or Zn. 4. The composition of claim 3, wherein X1 and X2 are carboxylic acids. 5. The composition of claim 4, wherein A1-A8 are C. 6. The composition of claim 5, wherein R1 and R10 are hydroxyls;R2-R5, R7, R9, R11 and R12 are hydrogen; andR6 and R8 are selected from the group consisting of (C1-C12)alkyl, (C1-C12)alkenyl, substituted (C1-C12)alkenyl, (C1-C12)alkynyl, substituted (C1-C12)alkynyl, hetero-(C1-C12)alkyl, substituted hetero-(C1-C12)alkyl, hetero-(C1-C12)alkenyl, substituted hetero-(C1-C12)alkenyl, hetero-(C1-C12)alkynyl, and substituted hetero-(C1-C12)alkynyl. 7. The composition of claim 6, wherein R6 and R8 are (C1-C6)alkyls. 8. The composition of claim 7, wherein z is a number from 1 to 15. 9. The composition of claim 1, wherein the MOF or IRMOF further comprises a post-framework reactant. 10. The composition of claim 9, wherein the post-framework reactant decreases the hydrophobicity of the framework. 11. The composition of claim 1, wherein at least one linking moiety comprises Formula I(a): 12. A composition comprising a pharmaceutically active agent and a MOF or IRMOF having the general structure M-L-M, wherein the pharmaceutically active agent is present in pores of the MOF or IRMOF, wherein M comprises a metal and L is a linking moiety, and wherein at least one linking moiety comprises Formula IV(a): 13. A composition comprising a pharmaceutically active agent and a MOF or IRMOF having the general structure M-L-M, wherein the pharmaceutically active agent is present in pores of the MOF or IRMOF, wherein M comprises a metal and L is a linking moiety, and wherein at least one linking moiety comprises Formula IV(b): wherein, y is a number from 0 to 20. 14. The composition of claim 1, wherein the pharmaceutically active agent is selected from the group consisting of a protein, a drug and a gas. 15. The composition of claim 12, wherein the pharmaceutically active agent is selected from the group consisting of a protein, a drug and a gas. 16. The composition of claim 13, wherein the pharmaceutically active agent is selected from the group consisting of a protein, a drug and a gas.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (27)
Dirk Johannes Bijl NL; Ronald Hage NL; Jan Kevelam NL; Jean Hypolites Koek NL; Dennis Stephen Murphy ; Irene Erica Smit NL; Johannes J. Verhagen NL; Pieter van der Vlist NL, Bleaching composition for dry cleaning containing transition metal bleach catalyst.
Yaghi, Omar M.; Matzger, Adam J.; Rowsell, Jesse L. C., Implementation of a strategy for achieving extraordinary levels of surface area and porosity in crystals.
Yaghi, Omar M.; Eddaoudi, Mohamed; Li, Hailian; Kim, Jaheon; Rosi, Nathaniel, Isoreticular metal-organic frameworks, process for forming the same, and systematic design of pore size and functionality therein, with application for gas storage.
Yaghi,Omar M.; Eddaoudi,Mohamed; Li,Hailian; Kim,Jaheon; Rosi,Nathaniel, Isoreticular metal-organic frameworks, process for forming the same, and systematic design of pore size and functionality therein, with application for gas storage.
Robert Timothy Stibrany ; Michael Gerard Matturro ; Stephen Zushma ; Abhimanyu Onkar Patil, Late transition metal catalyst complexes and oligomers therefrom.
Soo Hwaili (Charleston WV) Ream Bernard C. (Charleston WV) Robson John H. (Charleston WV), Mixed metal framework compositions for monoalkylene glycol production.
Mueller,Ulrich; Lippert,Gerald; Schubert,Olga; Hesse,Michael; Hess,Reinhard; Stoesser,Michael; Yaghi,Omar M., Process for preparing and organometallic framework material.
Mueller,Ulrich; Metelkina,Olga; Hesse,Michael; Stoesser,Michael; Haas,Peter; Yaghi,Omar, Process for the alkoxylation of monools in the presence of metallo-organic framework materials.
Mueller,Ulrich; Stoesser,Michael; Ruppel,Raimund; Baum,Eva; Bohres,Edward; Sigl,Marcus; Lobree,Lisa; Yaghi,Omar M.; Eddaoudi,Mohamed, Process for the alkoxylation of organic compounds in the presence of novel framework materials.
Muller, Ulrich; Lobree, Lisa; Hesse, Michael; Yaghi, Omar M.; Eddaoudi, Mohamed, Process for the epoxidation of an organic compound with oxygen or an oxygen-delivering compounds using catalysts containing metal-organic frame-work materials.
Ramprasad Dorai (Allentown PA) Pez Guido P. (Allentown PA) Pearlstein Ronald M. (Macungie PA) Meier Ingrid K. (Asbury NJ), Reversible oxygen sorbent compositions.
Chu Pochen (Voorhees NJ) Klocke Donald J. (Somerdale NJ) Marler David O. (Deptford NJ) McWilliams John P. (Woodbury NJ) Vartuli James C. (West Chester PA), Zeolite synthesis using an alcohol or like molecules.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.